Ribosome Biogenesis, Ribosomal Protein Alterations, and Tumor Suppressor p53 in Cancer: Molecular Mechanisms and Therapeutic Opportunities

Session

Pharmaceutical and Natural Sciences

Description

Ribosomes, as essential cellular machines for protein synthesis, are tightly regulated in normal cells but become dysregulated during cancer development, contributing to uncontrolled proliferation and biomass accumulation. Increased ribosome biogenesis and mutations in ribosomal proteins are hallmark features of many cancers. These alterations often lead to ribosomal stress, triggering p53-mediated cellular responses, a key tumor suppressor pathway frequently mutated or inactivated in malignancies. Advances in understanding ribosome-related molecular pathways have paved the way for novel anti-cancer therapies targeting ribosome biogenesis, ribosomal protein function, and associated signaling cascades. Additionally, the formation of polyploid giant cancer cells (PGCCs) contributes to tumor heterogeneity and resistance, representing further therapeutic challenges. This review summarizes the interplay between ribosome dynamics, p53 functions, ribosomal protein mutations, and the emerging therapeutic strategies focused on ribosome-directed approaches and PGCC targeting, highlighting promising compounds and future research directions.

Keywords:

Ribosome, Protein Synthesis, Cancer, PGCC

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-982-41-2

Location

UBT Lipjan, Kosovo

Start Date

25-10-2025 9:00 AM

End Date

26-10-2025 6:00 PM

DOI

10.33107/ubt-ic.2025.351

This document is currently not available here.

Share

COinS
 
Oct 25th, 9:00 AM Oct 26th, 6:00 PM

Ribosome Biogenesis, Ribosomal Protein Alterations, and Tumor Suppressor p53 in Cancer: Molecular Mechanisms and Therapeutic Opportunities

UBT Lipjan, Kosovo

Ribosomes, as essential cellular machines for protein synthesis, are tightly regulated in normal cells but become dysregulated during cancer development, contributing to uncontrolled proliferation and biomass accumulation. Increased ribosome biogenesis and mutations in ribosomal proteins are hallmark features of many cancers. These alterations often lead to ribosomal stress, triggering p53-mediated cellular responses, a key tumor suppressor pathway frequently mutated or inactivated in malignancies. Advances in understanding ribosome-related molecular pathways have paved the way for novel anti-cancer therapies targeting ribosome biogenesis, ribosomal protein function, and associated signaling cascades. Additionally, the formation of polyploid giant cancer cells (PGCCs) contributes to tumor heterogeneity and resistance, representing further therapeutic challenges. This review summarizes the interplay between ribosome dynamics, p53 functions, ribosomal protein mutations, and the emerging therapeutic strategies focused on ribosome-directed approaches and PGCC targeting, highlighting promising compounds and future research directions.